Cargando…

Epac‐induced ryanodine receptor type 2 activation inhibits sodium currents in atrial and ventricular murine cardiomyocytes

Acute RyR2 activation by exchange protein directly activated by cAMP (Epac) reversibly perturbs myocyte Ca(2+) homeostasis, slows myocardial action potential conduction, and exerts pro‐arrhythmic effects. Loose patch‐clamp studies, preserving in vivo extracellular and intracellular conditions, inves...

Descripción completa

Detalles Bibliográficos
Autores principales: Valli, Haseeb, Ahmad, Shiraz, Sriharan, Sujan, Dean, Lydia D, Grace, Andrew A, Jeevaratnam, Kamalan, Matthews, Hugh R, Huang, Christopher L‐H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814738/
https://www.ncbi.nlm.nih.gov/pubmed/29027245
http://dx.doi.org/10.1111/1440-1681.12870
_version_ 1783300395385225216
author Valli, Haseeb
Ahmad, Shiraz
Sriharan, Sujan
Dean, Lydia D
Grace, Andrew A
Jeevaratnam, Kamalan
Matthews, Hugh R
Huang, Christopher L‐H
author_facet Valli, Haseeb
Ahmad, Shiraz
Sriharan, Sujan
Dean, Lydia D
Grace, Andrew A
Jeevaratnam, Kamalan
Matthews, Hugh R
Huang, Christopher L‐H
author_sort Valli, Haseeb
collection PubMed
description Acute RyR2 activation by exchange protein directly activated by cAMP (Epac) reversibly perturbs myocyte Ca(2+) homeostasis, slows myocardial action potential conduction, and exerts pro‐arrhythmic effects. Loose patch‐clamp studies, preserving in vivo extracellular and intracellular conditions, investigated Na(+) current in intact cardiomyocytes in murine atrial and ventricular preparations following Epac activation. Depolarising steps to varying test voltages activated typical voltage‐dependent Na(+) currents. Plots of peak current against depolarisation from resting potential gave pretreatment maximum atrial and ventricular currents of −20.23 ± 1.48 (17) and −29.8 ± 2.4 (10) pA/μm(2) (mean ± SEM [n]). Challenge by 8‐CPT (1 μmol/L) reduced these currents to −11.21 ± 0.91 (12) (P < .004) and −19.3 ± 1.6 (11) pA/μm(2) (P < .04) respectively. Currents following further addition of the RyR2 inhibitor dantrolene (10 μmol/L) (−19.91 ± 2.84 (13) and −26.6 ± 1.7 (17)), and dantrolene whether alone (−19.53 ± 1.97 (8) and −27.6 ± 1.9 (14)) or combined with 8‐CPT (−19.93 ± 2.59 (12) and −29.9 ± 2.5(11)), were indistinguishable from pretreatment values (all P >> .05). Assessment of the inactivation that followed by applying subsequent steps to a fixed voltage 100 mV positive to resting potential gave concordant results. Half‐maximal inactivation voltages and steepness factors, and time constants for Na(+) current recovery from inactivation in double‐pulse experiments, were similar through all the pharmacological conditions. Intracellular sharp microelectrode membrane potential recordings in intact Langendorff‐perfused preparations demonstrated concordant variations in maximum rates of atrial and ventricular action potential upstroke, (dV/dt)(max). We thus demonstrate an acute, reversible, Na(+) channel inhibition offering a possible mechanism for previously reported pro‐arrhythmic slowing of AP propagation following modifications of Ca(2+) homeostasis, complementing earlier findings from chronic alterations in Ca(2+) homeostasis in genetically‐modified RyR2‐P2328S hearts.
format Online
Article
Text
id pubmed-5814738
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-58147382018-02-21 Epac‐induced ryanodine receptor type 2 activation inhibits sodium currents in atrial and ventricular murine cardiomyocytes Valli, Haseeb Ahmad, Shiraz Sriharan, Sujan Dean, Lydia D Grace, Andrew A Jeevaratnam, Kamalan Matthews, Hugh R Huang, Christopher L‐H Clin Exp Pharmacol Physiol Original Articles Acute RyR2 activation by exchange protein directly activated by cAMP (Epac) reversibly perturbs myocyte Ca(2+) homeostasis, slows myocardial action potential conduction, and exerts pro‐arrhythmic effects. Loose patch‐clamp studies, preserving in vivo extracellular and intracellular conditions, investigated Na(+) current in intact cardiomyocytes in murine atrial and ventricular preparations following Epac activation. Depolarising steps to varying test voltages activated typical voltage‐dependent Na(+) currents. Plots of peak current against depolarisation from resting potential gave pretreatment maximum atrial and ventricular currents of −20.23 ± 1.48 (17) and −29.8 ± 2.4 (10) pA/μm(2) (mean ± SEM [n]). Challenge by 8‐CPT (1 μmol/L) reduced these currents to −11.21 ± 0.91 (12) (P < .004) and −19.3 ± 1.6 (11) pA/μm(2) (P < .04) respectively. Currents following further addition of the RyR2 inhibitor dantrolene (10 μmol/L) (−19.91 ± 2.84 (13) and −26.6 ± 1.7 (17)), and dantrolene whether alone (−19.53 ± 1.97 (8) and −27.6 ± 1.9 (14)) or combined with 8‐CPT (−19.93 ± 2.59 (12) and −29.9 ± 2.5(11)), were indistinguishable from pretreatment values (all P >> .05). Assessment of the inactivation that followed by applying subsequent steps to a fixed voltage 100 mV positive to resting potential gave concordant results. Half‐maximal inactivation voltages and steepness factors, and time constants for Na(+) current recovery from inactivation in double‐pulse experiments, were similar through all the pharmacological conditions. Intracellular sharp microelectrode membrane potential recordings in intact Langendorff‐perfused preparations demonstrated concordant variations in maximum rates of atrial and ventricular action potential upstroke, (dV/dt)(max). We thus demonstrate an acute, reversible, Na(+) channel inhibition offering a possible mechanism for previously reported pro‐arrhythmic slowing of AP propagation following modifications of Ca(2+) homeostasis, complementing earlier findings from chronic alterations in Ca(2+) homeostasis in genetically‐modified RyR2‐P2328S hearts. John Wiley and Sons Inc. 2017-12-07 2018-03 /pmc/articles/PMC5814738/ /pubmed/29027245 http://dx.doi.org/10.1111/1440-1681.12870 Text en © 2017 The Authors. Clinical and Experimental Pharmacology and Physiology Published by John Wiley & Sons Australia, Ltd. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Valli, Haseeb
Ahmad, Shiraz
Sriharan, Sujan
Dean, Lydia D
Grace, Andrew A
Jeevaratnam, Kamalan
Matthews, Hugh R
Huang, Christopher L‐H
Epac‐induced ryanodine receptor type 2 activation inhibits sodium currents in atrial and ventricular murine cardiomyocytes
title Epac‐induced ryanodine receptor type 2 activation inhibits sodium currents in atrial and ventricular murine cardiomyocytes
title_full Epac‐induced ryanodine receptor type 2 activation inhibits sodium currents in atrial and ventricular murine cardiomyocytes
title_fullStr Epac‐induced ryanodine receptor type 2 activation inhibits sodium currents in atrial and ventricular murine cardiomyocytes
title_full_unstemmed Epac‐induced ryanodine receptor type 2 activation inhibits sodium currents in atrial and ventricular murine cardiomyocytes
title_short Epac‐induced ryanodine receptor type 2 activation inhibits sodium currents in atrial and ventricular murine cardiomyocytes
title_sort epac‐induced ryanodine receptor type 2 activation inhibits sodium currents in atrial and ventricular murine cardiomyocytes
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814738/
https://www.ncbi.nlm.nih.gov/pubmed/29027245
http://dx.doi.org/10.1111/1440-1681.12870
work_keys_str_mv AT vallihaseeb epacinducedryanodinereceptortype2activationinhibitssodiumcurrentsinatrialandventricularmurinecardiomyocytes
AT ahmadshiraz epacinducedryanodinereceptortype2activationinhibitssodiumcurrentsinatrialandventricularmurinecardiomyocytes
AT sriharansujan epacinducedryanodinereceptortype2activationinhibitssodiumcurrentsinatrialandventricularmurinecardiomyocytes
AT deanlydiad epacinducedryanodinereceptortype2activationinhibitssodiumcurrentsinatrialandventricularmurinecardiomyocytes
AT graceandrewa epacinducedryanodinereceptortype2activationinhibitssodiumcurrentsinatrialandventricularmurinecardiomyocytes
AT jeevaratnamkamalan epacinducedryanodinereceptortype2activationinhibitssodiumcurrentsinatrialandventricularmurinecardiomyocytes
AT matthewshughr epacinducedryanodinereceptortype2activationinhibitssodiumcurrentsinatrialandventricularmurinecardiomyocytes
AT huangchristopherlh epacinducedryanodinereceptortype2activationinhibitssodiumcurrentsinatrialandventricularmurinecardiomyocytes